Ads
related to: radiation protection iodide treatment for cancer
Search results
Results From The WOW.Com Content Network
As it decays, it may cause damage to the thyroid. The primary risk from exposure to 131 I is an increased risk of radiation-induced cancer in later life. Other risks include the possibility of non-cancerous growths and thyroiditis. [5] The risk of thyroid cancer in later life appears to diminish with increasing age at time of exposure.
Iodine-125 (125 I) is a radioisotope of iodine which has uses in biological assays, nuclear medicine imaging and in radiation therapy as brachytherapy to treat a number of conditions, including prostate cancer, uveal melanomas, and brain tumors. It is the second longest-lived radioisotope of iodine, after iodine-129.
Potassium iodide (KI) and potassium iodate (KIO 3) are called thyroid blockers when used in radiation protection. [1] [2] [3] [4]
Unprotected experiments in the U.S. in 1896 with an early X-ray tube (Crookes tube), when the dangers of radiation were largely unknown.[1]The history of radiation protection begins at the turn of the 19th and 20th centuries with the realization that ionizing radiation from natural and artificial sources can have harmful effects on living organisms.
Potassium iodide is a chemical compound, medication, and dietary supplement. [4] [5] It is a medication used for treating hyperthyroidism, in radiation emergencies, and for protecting the thyroid gland when certain types of radiopharmaceuticals are used. [6]
Iodine-125 is also commonly used by radiation oncologists in low dose rate brachytherapy in the treatment of cancer at sites other than the thyroid, especially in prostate cancer. When 125 I is used therapeutically, it is encapsulated in titanium seeds and implanted in the area of the tumor, where it remains.
Ads
related to: radiation protection iodide treatment for cancer